Navigation Links
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Date:11/26/2008

at involve a number of risks and uncertainties, including whether the closing conditions, including the consent of Biogen Idec, Inc., will be satisfied in order to consummate the joint venture transaction, the success of the joint venture in commercializing and developing ZEVALIN, the ability of the joint venture to accelerate top-line revenues in the near-term, and the ability to integrate ZEVALIN into Spectrum's commercial, marketing and medical affairs teams ,the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of ZEVALIN include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN in particular including, without limitation, the potential for ZEVALIN FIT data to be acceptable to the FDA for this expanded indication or any other indication, the potential that the FDA will not grant priority review to the sBLA, the ability of CTI to continue to raise capital to fund its operations, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling ZEVALIN. There is also a risk that even if label expansion of ZEVALIN is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

     Spectrum Contacts
     Russell Skibsted - Chief Busi
'/>"/>
SOURCE Spectrum Pharmaceuticals, Inc.; Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
2. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
3. "Brave New Reality" Provides a Wide Spectrum of High Tech News and Easy Science.
4. Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale
5. Energetiqs Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet
6. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Global Experts Explore Entire Spectrum of Aids Vaccine Development
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Fla. , July 30, 2014  Dyadic ... biotechnology company whose patented and proprietary technologies are ... and other proteins for the bioenergy, bio-based chemical, ... appointment of Thomas "Tom" Dubinski as Vice President ... for leading the financial and information technology operations ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel drug ... seed financing from friends and family investors. Proceeds from ... novel sustained-release product for ophthalmology. , "We are grateful ... to this important work," said Dr. Ken Mandell, Founder ... areas in which innovations in drug delivery have already ...
(Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... million from Merz Pharmaceuticals GmbH (Merz) for ... Memantine for the treatment of,moderate-to-severe Alzheimer,s disease ... an exclusive marketing agreement, NTI currently receives,quarterly ...
... CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today announced ... CEO of Andros Men,s Health Institutes,in The Netherlands, ... a Poster,Session at the 23rd Annual European Association ...
... ... First Non-GAAP Profit; Sales Guidance Revised Upward, ... Neurology and Cancer, First Quarter 2008 Financial Highlights:, - Soliris(R) (eculizumab) net product sales were ... Q4 2007., - Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, ...
Cached Biology Technology:AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6Alexion Reports First Quarter 2008 Results 2Alexion Reports First Quarter 2008 Results 3Alexion Reports First Quarter 2008 Results 4Alexion Reports First Quarter 2008 Results 5Alexion Reports First Quarter 2008 Results 6Alexion Reports First Quarter 2008 Results 7Alexion Reports First Quarter 2008 Results 8Alexion Reports First Quarter 2008 Results 9Alexion Reports First Quarter 2008 Results 10Alexion Reports First Quarter 2008 Results 11Alexion Reports First Quarter 2008 Results 12
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
(Date:7/29/2014)... In the high-tech world of science, researchers sometimes ... Barbara,s Douglas McCauley did just that to study ... muricatum ) on coral reef ecosystems at two ... Using direct observation, animal tracking and computer simulation, ... Ecology, Evolution and Marine Biology, and his colleagues ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Underwater elephants 2Underwater elephants 3
... 2013)In a series of papers to be presented next ... mechanism operating in the roots of a tropical grass ... greenhouse gas emissions. Referred to as "biological nitrification ... of nitrogen applied to soil as fertilizer into nitrous ...
... This news release is available in German ... daughter; like father, like son. Evolutionary biologists at the universities in ... also applies to inheriting a long life at least for ... descendants of these insects mostly inherit their lifespan from their own ...
... disease indicate future joint problems? Although researchers and clinicians ... chronic inflammatory diseases - periodontal disease and rheumatoid arthritis ... In an article published today in PLOS Pathogens ... and Systemic Diseases group researcher Jan Potempa, PhD, DSc, ...
Cached Biology News:'Grassroots action' in livestock feeding to help curb global climate change 2'Grassroots action' in livestock feeding to help curb global climate change 3'Grassroots action' in livestock feeding to help curb global climate change 4Inheritance of lifespan is sex-dependent in fruit flies 2Bacteria responsible for gum disease facilitates rheumatoid arthritis 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Biology Products: